Viking Therapeutics, Inc. (NASDAQ:VKTX) declined to $8.90. On Apr, 15 it was reported by Barchart.com. Viking Therapeutics, Inc. (NASDAQ:VKTX) has $640.69 million market cap. The valuation of NASDAQ:VKTX can change by $57.66 million if our $8.10 target is touched.

Viking Therapeutics, Inc. (NASDAQ:VKTX) Ratings Coverage

Total analysts of 4 have positions in Viking Therapeutics (NASDAQ:VKTX) as follows: 4 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 19, 2018 according to StockzIntelligence Inc Viking Therapeutics has 10 analyst reports. The company rating was maintained by FBR Capital on Thursday, March 14. On Monday, November 19 the company was upgraded by Raymond James. On Thursday, March 14 the firm earned “Buy” rating by Maxim Group. In Thursday, March 14 report H.C. Wainwright maintained it with “Buy” rating and $31 target. The stock rating was initiated by Leerink Swann with “Hold” on Friday, February 22. On Thursday, March 14 the firm earned “Strong Buy” rating by Raymond James.

For more Viking Therapeutics, Inc. (NASDAQ:VKTX) news announced recently go to: Nasdaq.com, Seekingalpha.com, Schaeffersresearch.com, Globenewswire.com or Streetinsider.com. The titles are as follows: “Here’s Why Investors Are Betting Against These 2 Biotech Stocks – Nasdaq” announced on April 06, 2019, “RIOT, AMRS among premarket gainers – Seeking Alpha” on March 27, 2019, “3 Pharma Stocks Expected to Double – Schaeffers Research” with a publish date: March 29, 2019, “Consolidated Research: 2019 Summary Expectations for Ctrip.com International, Anadarko Petroleum, Viking Therapeutics, Bruker, Tech Data, and Sierra Wireless — Fundamental Analysis, Key Performance Indications – GlobeNewswire” and the last “Viking (VKTX) to Present New Data from Phase 2 Study of VK2809 in Patients with NAFLD and Elevated LDL-Cholesterol – StreetInsider.com” with publication date: April 04, 2019.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders.The firm is valued at $640.69 million. The Company’s lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery.Currently it has negative earnings. The firm also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder.